<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733031</url>
  </required_header>
  <id_info>
    <org_study_id>D2785C00002</org_study_id>
    <nct_id>NCT00733031</nct_id>
  </id_info>
  <brief_title>Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to find out what the maximum tolerated dose is for an
      experimental drug called AZD6918 based on the side effects experienced by patients with
      advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918
      will be administered twice daily. Then maximum tolerated doses in combination with either
      gemcitabine or pemetrexed will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PK results demonstrate low and variable plasma concentrations so that achieving therapeutic
    concentrations is unlikely.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (based on CTCAE version 3.0), laboratory values, vital sign measurements, Karnofsky performance status</measure>
    <time_frame>Weekly for first two treatment cycles, then every 2-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect of AZD6918 when administered alone and in combination with chemotherapy</measure>
    <time_frame>According to protocol specified schedule, the number of PK samples collected during Cycle 1 (up to 28 days) based on treatment with AZD6918 alone or in combination with chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cancer,</condition>
  <condition>Solid Tumors</condition>
  <condition>Advanced Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine administered in combination with AZD6918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pemetrexed administered in combination with AZD6918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD6918</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD6918 administered alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6918</intervention_name>
    <description>liquid suspension, daily, oral dose</description>
    <arm_group_label>AZD6918</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>intravenous, doses are on an intermittent schedule</description>
    <arm_group_label>gemcitabine</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>intravenous, dose administered every 21-days</description>
    <arm_group_label>pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumors for which standard treatment does not exist or is no longer
             effective.

          -  For chemotherapy combination treatment, must be suitable for treatment with either
             gemcitabine or pemetrexed.

          -  Relatively good overall health other than cancer.

        Exclusion Criteria:

          -  Poor bone marrow function (not producing enough blood cells).

          -  Poor liver or kidney function.

          -  Serious heart conditions

          -  History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain
             tumor or any uncontrolled psychiatric or nervous system condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Ochs, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Infante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lia Gore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>December 9, 2010</last_update_submitted>
  <last_update_submitted_qc>December 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Judith Ochs, M.D. Medical Science Director</name_title>
    <organization>AstraZeneca Pharmaceuticals, LP</organization>
  </responsible_party>
  <keyword>Phase I,</keyword>
  <keyword>cancer,</keyword>
  <keyword>solid tumors,</keyword>
  <keyword>advanced solid malignancies,</keyword>
  <keyword>dose escalation,</keyword>
  <keyword>combination treatment,</keyword>
  <keyword>TRK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

